Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system…
| Price | $7.76 |
|---|---|
| Market cap | $2.76B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 2.99-8.0385 |
| Beta | 1.02 |
Explore PGEN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.